Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We used functional magnetic resonance imaging to investigate the effects of short-term treatment with reboxetine, a selective noradrenaline reuptake inhibitor, on emotional facial processing in healthy volunteers. Reboxetine was associated with a reduced amygdala response to fearful faces and increased activation to happy v. neutral facial expressions in the right fusiform gyrus, relative to placebo treatment and in the absence of changes in mood. Our results show that reboxetine modulates the neural substrates of emotional processing, highlighting a mechanism by which drug treatment could normalise negative bias in depression and anxiety.

Original publication

DOI

10.1192/bjp.bp.106.031393

Type

Journal article

Journal

Br J Psychiatry

Publication Date

06/2007

Volume

190

Pages

531 - 532

Keywords

Antidepressive Agents, Facial Expression, Female, Humans, Magnetic Resonance Imaging, Male, Morpholines, Pattern Recognition, Visual, Treatment Outcome